ET-700 Pilot Shows Cleaner Safety but Weaker Copper Blocking Than GALZIN
ETON has more than doubled off its 52-week low of $14.27.
Summary
Eton's investigational ET-700 cut hepatic copper uptake by 12% in the per-protocol analysis of a four-week healthy-volunteer study, versus 46% for GALZIN. The tolerability side is the win: treatment-related GI events ran at 0.30 versus 5.35 per 100 participant-days, with no serious adverse events. The intent-to-treat read showed the same gap (18% vs 58%, p=0.023), so the weaker efficacy is not a statistical artifact. The study is small — 36 safety participants, 29 per protocol — and enrolled healthy volunteers, not Wilson disease patients, so nothing here establishes clinical benefit. Eton plans faster-release formulation arms in 2027 to try to close the copper-blocking gap while keeping the tolerability edge. This lands alongside the Q3 release showing EPS of $1.06, so the commercial story is carrying the stock while ET-700 remains early-stage optionality.
At the time of this announcement, ETON was trading at $58.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $14.27 to $66.37. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.